Source Articles
Sorafenib
Showing 2 study arms
with grade ≥3 adverse event data (treatment-related and RT-related).
Click a column header to sort.
Note on patient counts: some articles reported only percentages rather
than absolute numbers. Where this occurred, the number of patients — including those with
grade ≥3 adverse events — was derived by applying the reported percentage to the total arm
size, which may produce a non-integer value. These figures have been rounded to the nearest
integer for display.
| 1st Author | Year | Study Type | Title | DOI | clinical trial number | number of patients | median/mean age | median follow-up [months] | tumor type | treatment setting | drug group | drug name | if other, please specify | number of SBRT courses | intracranial / extracranial | treated site | If other treated site, please specify | median/mean total RT dose [Gy] | minimum total RT dose [Gy] | maximum total RT dose [Gy] | median/mean number of fractions | minimum number of fractions | maximum number of fractions | median/mean dose per fraction [Gy] | minimum dose per fraction [Gy] | maximum dose per fraction [Gy] | toxicity type | patients with acute G>=3 toxicity | patients with late G>=3 toxicity | patients with G>=3 toxicity, timing unspecified | G>=3 AEs | patients with G>=3 AEs | details on G>=3 toxicity | details on G>=3 toxicity in RT field |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dawson et al. | 2025 | Prospective | Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial. | 10.1001/jamaoncol.2024.5403 | NCT01730937 | 83 | 66 | 13.2 | HCC | primary | Multi-target TKI | Sorafenib | — | 83 | extra-cranial | liver | — | Missing | 20 | 50 | Missing | 2 | 5 | Missing | 6 | 10 | Treatment-rel. | — | — | 39 | any G3: 35 AEs, any G4: 3 AEs, any G5: 1 AE | any G3: 35 pts, any G4: 3 pts, any G5: 1 pt |
any G3: nausea, vomiting, diarrhea, duodenal perforation, duodenal ulcer, ascites, gastric/upper GI hemorrhage, lower GI hemorrhage, alanine aminotransferase increased, aspartatte aminotrasnferase increased, blood bilirubin increased, platelet count decreased, skin, hypertension, any G4: hepatic failure, hepatic hemorrhage, platelet count decreased, any G5: lung infection
|
—
|
| Goody et al. | 2017 | Prospective | Phase I trial of radiation therapy and sorafenib in unresectable liver metastases | 10.1016/j.radonc.2017.01.018 | NCT00892424 | 18 | 62 | Missing | Breast cancer, Colorectal cancer, Melanoma, other | primary, metastatic | Multi-target TKI | Sorafenib | — | 18 | extra-cranial | liver | — | Missing | 30 | 60 | 6 | 6 | 6 | Missing | 5 | 10 | Treatment-rel. | 10 | — | — | acute G3: 8, acute G4: 1 | acute G3: unknown pts, acute G4: 1 pt |
acute G3: generalized skin toxicity, hand foot syndrome, musculoskeletal, abdominal pain, hyponatremia, hypophosphatemia, acute G4: abdominal pain
|
acute G3: abdominal pain
|